Congress targets breast cancer disparities affecting women of color
H.R. 1806 — Triple-Negative Breast Cancer Research and Education Act of 2025 · Filed by Joseph Morelle (D-NY) · 13 cosponsors · Introduced Mar 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health to expand research into triple-negative breast cancer (an aggressive form that disproportionately affects African-American and Hispanic women) and requires the CDC and Health Resources and Services Administration to develop and distribute public education and provider training materials about the disease. The bill authorizes funding for these research and education activities from 2026 through 2031, with no specific dollar amount specified.
Why we flagged it
The bill's functional purpose is to authorize NIH research and CDC/HRSA education programs targeting a specific disease with documented health disparities. It is straightforward public health legislation with no hidden provisions or narrow beneficiaries.
What the text implies
- The bill authorizes but does not appropriate specific funding amounts, meaning actual resources depend on future congressional appropriations decisions—research may be underfunded or delayed if Congress does not follow through.
- By focusing research and education on triple-negative breast cancer specifically, the bill may indirectly increase awareness and early detection among minority women, potentially improving survival disparities documented in the findings.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies developing breast cancer treatments; research institutions and universities conducting NIH-funded studies; nonprofit organizations and media outlets contracted for public education